Originally posted by AllSeq
View Post
Unconfigured Ad
Collapse
X
-
Should have said they've not been 'launched'. They certainly may have been 'released' in the form of early access.
-
-
Comment
-
-
Originally posted by GenoMax View PostI thought the only default option one had was to deny existence/all knowledge of the "entity" that was subject of a NDA. I was surprised at your admission in that context.
I'm from New Jersey...we bury NDA's in the Meadowlands or under Giants Stadium.
Comment
-
-
The embargo has been lifted so we can finally talk about the new Ion S5 – it’s basically a streamlined combination of the PGM and Proton made as easy to use as possible for ‘novice users’. See our blog post for more details and then tell us what you think: A useful addition to the NGS market? Too little too late?
Comment
-
-
We haven't seen list prices, but we asked during the media event and they said "roughly in line with current PGM and Proton prices". It sounds like the kits may be a bit higher, but the 'per sample' pricing should more or less be the same.Originally posted by GW_OK View PostDoes anyone know reagent costs? All I'm seeing discussed is equipment price.
Comment
-
-
As far as I can tell, costs are almost the same when comparing PGM-318 vs S5-520 and Proton PI vs S5-540. Correct?
So really what is missing with the S5 is the low-output low-cost option of the PGM-314 and -316. Not sure if that is such a smart idea, since there are labs around that want to run a low throughput sample quickly without waiting for more samples to come in. That has been one of the big plus points for Ion IMHO, plus the extremely well working Ampliseq custom panels......
Comment
-
-
I can't really address the Proton (we don't use them in our labs), but we have PGM's running in our CAP-CLIA facility and we will, for the most part, be using them for development work going forward. All of our production is going to the S5's (we have the XL and are ordering more). When coupled to the CHEF it makes for an extremely efficient workflow (we run AmpliSeq panels) and I suspect other diagnostic labs will be very happy with this combo. We have validated the CHEF-S5XL in our processes and we really like the 540 chip. It gives us a lot of "head-space" and is very cost effective for our larger projects.Originally posted by Xray1 View PostAs far as I can tell, costs are almost the same when comparing PGM-318 vs S5-520 and Proton PI vs S5-540. Correct?
So really what is missing with the S5 is the low-output low-cost option of the PGM-314 and -316. Not sure if that is such a smart idea, since there are labs around that want to run a low throughput sample quickly without waiting for more samples to come in. That has been one of the big plus points for Ion IMHO, plus the extremely well working Ampliseq custom panels......
As far as the quality of sequencing, so far, so good (maybe even a bit better than the PGM).
Comment
-
Latest Articles
Collapse
-
by SEQadmin2
Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.
The systematic characterization of the human proteome has...-
Channel: Articles
07-20-2026, 11:48 AM -
-
by SEQadmin2
Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
...-
Channel: Articles
07-09-2026, 11:10 AM -
-
by SEQadmin2
Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.
There is no single reason why many patients don’t respond to treatment as expected. Cancer is...-
Channel: Articles
07-08-2026, 05:17 AM -
ad_right_rmr
Collapse
News
Collapse
| Topics | Statistics | Last Post | ||
|---|---|---|---|---|
|
Started by SEQadmin2, Yesterday, 11:41 AM
|
0 responses
9 views
0 reactions
|
Last Post
by SEQadmin2
Yesterday, 11:41 AM
|
||
|
Started by SEQadmin2, 07-20-2026, 11:10 AM
|
0 responses
23 views
0 reactions
|
Last Post
by SEQadmin2
07-20-2026, 11:10 AM
|
||
|
Started by SEQadmin2, 07-13-2026, 10:26 AM
|
0 responses
36 views
0 reactions
|
Last Post
by SEQadmin2
07-13-2026, 10:26 AM
|
||
|
Started by SEQadmin2, 07-09-2026, 10:04 AM
|
0 responses
45 views
0 reactions
|
Last Post
by SEQadmin2
07-09-2026, 10:04 AM
|
Comment